Evommune vs Palatin Technologies
EVMN and PTN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVMN and PTN compare
Evommune is the larger company, worth 25 times as much as Palatin Technologies ($277M against $11.1M).
Evommune scores higher on the StockData Score (7 against 6 for Palatin Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVMN | PTN |
|---|---|---|
| Size and price | ||
| Market cap | $277M | $11.1M |
| Share price | $7.63 | $6.23 |
| Change, 1 year | −60.9% | −43.6% |
| Change, 5 years | – | −98.6% |
| Beta (5Y) | 0.79 | 0.77 |
| Employees | 48 | 25 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.1× (better) | 1.7× |
| FCF yield | −32.9% (better) | −122% |
| Growth | ||
| Revenue growth (TTM) | −100% | – |
| Profitability | ||
| Return on equity | −331% (better) | −878% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −1288.8× |
| Current ratio | 8.52 (better) | 4.61 |
| Altman Z-score | 3.85 (better) | −75.61 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −152% |
| Shareholder yield | 0.00% (better) | −152% |
| Ownership | ||
| Held by institutions | 95.4% | 38.5% |
| Held by insiders | 51.6% | 20.6% |
| Insider net buying, 12 months | −$2.1M | −$9.5K (better) |
| Short interest, % of float | 19.3% | 20.9% |
Go deeper
- EVMN stock overview
- EVMN income statement
- EVMN valuation and score
- PTN stock overview
- PTN income statement
- PTN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.